Date of Award
Selective Evidence-Based Medicine Review
Master of Science in Health Sciences - Physician Assistant
Physician Assistant Studies
John Cavenagh, MBA, PhD, PA-C
Objective: The objective of this systematic review is to determine how well leukotriene inhibitors/modifiers reduce symptoms associated with nasal polyps.
Study Design: The studies included in this review are three randomized controlled trials.
Data Source: The three RCTs in this review were obtained by performing a PubMed search using the keywords “nasal polyp”, “leukotriene”, and “Montelukast”. All articles were published in English and in peer-reviewed journals.
Outcomes Measured: The three studies determine whether there was significant improvement of symptoms in patients with nasal polyps who were treated adjunctively with leukotriene inhibitors/modifiers. The symptoms were measured before and after the treatments using three different symptom score guidelines.
Results: Patients who were diagnosed with chronic rhinosinusitis with nasal polyposis who were given Montelukast (leukotriene inhibitor) as adjunctive therapy demonstrated statistically significant reduction in symptoms, p<0.05. In all three studies, Wu et al10, Yelverton et al11, Suri et al12 the symptom scores decreased significantly in comparison to patients who received no Montelukast adjunctive therapy.
Conclusions: Based on the systematic review of the three randomized controlled trials, one can decisively say that leukotriene inhibitors/modifiers (Montelukast) can reduce the symptoms associated with the presence of nasal polyps. All three studies verified statistically significant reduction in symptoms compared to the control groups.
Knox, Dallas A., "Do leukotriene inhibitors/modifiers reduce symptoms associated with Nasal Polyps?" (2018). PCOM Physician Assistant Studies Student Scholarship. 368.